During the first half of the year, the company generated cash from operations of $1.4 billion and ended the quarter with cash and cash equivalents of $3.9 billion. The company deployed $191 million for acquisitions during the first half of the fiscal year.
The company’s success can be attributed to strong growth in U.S. pharmaceutical direct distribution and services revenues as well as the acquisition of US Oncology.
Related Articles on McKesson:
McKesson to Administer Cephalon Programs for Cancer Pain
CMS Chooses McKesson’s InterQual Criteria for Medicare Inpatient Services Audit Program
McKesson Partners With Lakewood Health System
